FKBPL Antibody

1. This study identified two low-frequency nonsynonymous variants at FKBPL (rs200847762, OR = 0.34, 95% CI = 0.20-0.57, P = 4.31 x 10-5) and ARPC1B (rs1045012, OR = 0.56, 95% CI = 0.43-0.74, P = 4.30 x 10-5) associated with breast cancer risk. PMID: 27479355
2. The data suggests a role for FKBPL as a prognostic factor for BCSS, with the potential to be routinely evaluated within the clinic. PMID: 25906750
3. WISp39 preferentially interacts with phosphorylated Coronin 1B, allowing it to complex with Slingshot phosphatase to dephosphorylate and activate Cofilin. PMID: 25800056
4. FKBPL is an important regulator of developmental and pathological angiogenesis. PMID: 25767277
5. high levels of FKBPL and RBCK1 correlated with increased patient survival, whereas high RBCK1 predicted for a poor response to tamoxifen. PMID: 23912458
6. FKBPL and and its peptide derivative, AD-01 regulate expression of CD44. PMID: 23457460
7. Genome-wide association study of age-related macular degeneration identifies TNXB, FKBPL and NOTCH4 as candidate susceptibility genes. PMID: 22694956
8. Alterations in the gene for FKBPL in azoospermic patients. PMID: 20210997
9. Findings suggest that FKBPL may have prognostic value based on its impact on tumor proliferative capacity and sensitivity to endocrine therapies, which improve outcome. PMID: 20103631
10. Results demonstrate the importance of posttranslational stabilization of p21 protein by WISp39 in regulating cellular p21 activity. PMID: 15664193
11. FKBPL can be classed as a new member of the FKBP protein family with a role in steroid receptor complexes and signaling. PMID: 18669603

Show More

Hide All

HGNC: 13949

KEGG: hsa:63943

STRING: 9606.ENSP00000364298

UniGene: Hs.520042